Literature DB >> 2461799

Human lung carcinoma monoclonal antibody specific for the Thomsen-Friedenreich antigen.

R Stein1, S Chen, W Grossman, D M Goldenberg.   

Abstract

A monoclonal antibody, RS1-114, was raised against the human adenocarcinoma of the lung cell line A549. By studying the reactivity of RS1-114 with A549 cells following chemical and enzymatic treatments, it was shown that the epitope is a galactose-containing carbohydrate, which is devoid of sialic acid. Hemagglutination of desialylated RBCs, enzyme-linked immunosorbent assay studies with glycoprotein antigens before and after desialylation, and competition studies using peanut agglutinin indicate that monoclonal antibody RS1-114 recognizes the Thomsen-Friedenreich antigen, a cryptic determinant on human erythrocytes which can be exposed by neuraminidase treatment. It is expressed in an unhidden form on a large percentage of carcinomas and is therefore an important human tumor marker. RS1-114 is reactive with cryptic determinants of the Thomsen-Friedenreich antigen on white blood cells as well as red blood cells, and it reacts with unhidden determinants on human tumor cell lines. The number of binding sites on carcinoma cells is further increased by neuraminidase treatment. By immunohistochemical staining, it was shown that 75% of the human tumors tested are reactive with RS1-114. These include tumors of the breast, colon, lung, kidney, ovary, and rectum.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2461799

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.

Authors:  R Stein; E Belisle; H J Hansen; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

2.  SPECIFIC MOLECULAR RECOGNITION AS A STRATEGY TO DELINEATE TUMOR MARGIN USING TOPICALLY APPLIED FLUORESCENCE EMBEDDED NANOPARTICLES.

Authors:  Shawn Barton; Bo Li; Michael Siuta; Janve Vaibhav; Jessica Song; Clinton M Holt; Takumi Tomono; Masami Ukawa; Hironori Kumagai; Etsuo Tobita; Kevin Wilson; Shinji Sakuma; Wellington Pham
Journal:  Precis Nanomed       Date:  2018-10-29

3.  Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.

Authors:  Rhona Stein; Zhengxing Qu; Susan Chen; David Solis; Hans J Hansen; David M Goldenberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

4.  Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs.

Authors:  G V Glinsky; V V Mossine; J E Price; D Bielenberg; V V Glinsky; H N Ananthaswamy; M S Feather
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

5.  The human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies.

Authors:  B Jansson; C A Borrebaeck
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.

Authors:  Rhona Stein; Mitchell R Smith; Susan Chen; Maria Zalath; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

7.  Coexpression of cancer-associated carbohydrate antigens, Tn and sialyl Tn.

Authors:  H Nakada; M Inoue; N Tanaka; I Yamashina
Journal:  Glycoconj J       Date:  1994-06       Impact factor: 2.916

8.  Sclerotium rolfsii lectin induces opposite effects on normal PBMCs and leukemic Molt-4 cells by recognising TF antigen and its variants as receptors.

Authors:  Vishwanath B Chachadi; Radha Pujari; Padma Shastry; Bale M Swamy; Shashikala R Inamdar
Journal:  Glycoconj J       Date:  2020-01-04       Impact factor: 2.916

9.  The role of the Thomsen-Friedenreich antigen as a tumor-associated molecule.

Authors:  W Dippold; A Steinborn; K H Meyer zum Büschenfelde
Journal:  Environ Health Perspect       Date:  1990-08       Impact factor: 9.031

10.  Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas.

Authors:  Yanfei Xu; Sandra J Gendler; Alessandra Franco
Journal:  J Exp Med       Date:  2004-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.